| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Advances in Brief |
Department of Molecular Oncology [B. T., Y. F., D. S. B. H.] and Division of Biostatistics [H-J. W.], John Wayne Cancer Institute, Saint John’s Health Center, Santa Monica, California 90404 [L. J. F., D. L. M.]
Purpose: Multiple genetic alterations including loss of heterozygosity (LOH) occur commonly in melanoma tumors. We demonstrated previously free-circulating DNA microsatellites with LOH in the blood of melanoma patients. These LOH markers in plasma may be useful as surrogates for subclinical disease progression. The purpose of this study was to determine whether the presence of circulating tumor microsatellite markers in the preoperative blood from patients with melanoma has prognostic utility.
Experimental Design: Plasma was analyzed for the presence of LOH at six chromosome regions, which are common for allelic loss in melanoma tumors, in 57 patients undergoing surgical resection of all of the clinically apparent disease.
Results: LOH was detected in 32 of 57 patients (56%). Both LOH incidence and frequency correlated with advancing American Joint Committee on Cancer stage. In patients with American Joint Committee on Cancer stage III, the presence of LOH as an independent variable in preoperative plasma was significantly associated (P = 0.05) with an increased risk of death. Furthermore, LOH at microsatellite marker D1S228 in the plasma of patients with advanced disease correlated significantly (P = 0.0009) with a poorer survival after surgical resection. LOH commonly found in melanoma tumors can be successfully identified in the plasma of a patient, providing a potentially less invasive route for following genetic changes that serve as molecular surrogates for assessing subclinical disease progression.
Conclusions: This study provides evidence that blood testing for circulating tumor genetic markers may provide valuable prognostic information and guide future therapy.
This article has been cited by other articles:
|
|
 |
|
  J. M. Garcia, C. Pena, V. Garcia, G. Dominguez, C. Munoz, J. Silva, I. Millan, R. Diaz, Y. Lorenzo, R. Rodriguez, et al. Prognostic Value of LISCH7 mRNA in Plasma and Tumor of Colon Cancer Patients Clin. Cancer Res., November 1, 2007; 13(21): 6351 - 6358. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Salani, B. Davidson, M. Fiegl, C. Marth, E. Muller-Holzner, G. Gastl, H.-Y. Huang, J.-C. Hsiao, H.-S. Lin, T.-L. Wang, et al. Measurement of Cyclin E Genomic Copy Number and Strand Length in Cell-Free DNA Distinguish Malignant versus Benign Effusions Clin. Cancer Res., October 1, 2007; 13(19): 5805 - 5809. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Garcia, J. M. Garcia, C. Pena, J. Silva, G. Dominguez, A. Hurtado, I. Alonso, R. Rodriguez, M. Provencio, and F. Bonilla Thymidylate synthase messenger RNA expression in plasma from patients with colon cancer: prognostic potential. Clin. Cancer Res., April 1, 2006; 12(7): 2095 - 2100. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Taback, S. J. O'Day, P. D. Boasberg, S. Shu, P. Fournier, R. Elashoff, H.-J. Wang, and D. S. B. Hoon Circulating DNA Microsatellites: Molecular Determinants of Response to Biochemotherapy in Patients With Metastatic Melanoma J Natl Cancer Inst, January 21, 2004; 96(2): 152 - 156. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Taback, A. E. Giuliano, N. M. Hansen, F. R. Singer, S. Shu, and D. S. B. Hoon Detection of Tumor-Specific Genetic Alterations in Bone Marrow from Early-Stage Breast Cancer Patients Cancer Res., April 15, 2003; 63(8): 1884 - 1887. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Silva, J. Silva, A. Sanchez, J. M. Garcia, G. Dominguez, M. Provencio, L. Sanfrutos, E. Jareno, A. Colas, P. Espana, et al. Tumor DNA in Plasma at Diagnosis of Breast Cancer Patients Is a Valuable Predictor of Disease-free Survival Clin. Cancer Res., December 1, 2002; 8(12): 3761 - 3766. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. Johnson and Y.M. D. Lo Plasma Nucleic Acids in the Diagnosis and Management of Malignant Disease Clin. Chem., August 1, 2002; 48(8): 1186 - 1193. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Dominguez, J. Carballido, J. Silva, J. M. Silva, J. M. Garcia, J. Menendez, M. Provencio, P. Espana, and F. Bonilla p14ARF Promoter Hypermethylation in Plasma DNA as an Indicator of Disease Recurrence in Bladder Cancer Patients Clin. Cancer Res., April 1, 2002; 8(4): 980 - 985. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
